SRR8942946
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.440
- INTERFERON_GAMMA_RESPONSE+0.330
- TGF_BETA_SIGNALING+0.320
- ALLOGRAFT_REJECTION+0.290
- NOTCH_SIGNALING+0.230
- P53_PATHWAY+0.220
- WNT_BETA_CATENIN_SIGNALING+0.170
- UV_RESPONSE_DN+0.140
- IL6_JAK_STAT3_SIGNALING+0.130
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.130
Top 10 suppressed
- E2F_TARGETS-0.610
- G2M_CHECKPOINT-0.540
- CHOLESTEROL_HOMEOSTASIS-0.430
- MTORC1_SIGNALING-0.370
- SPERMATOGENESIS-0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.290
- ESTROGEN_RESPONSE_LATE-0.280
- UV_RESPONSE_UP-0.250
- PANCREAS_BETA_CELLS-0.240
- HEDGEHOG_SIGNALING-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12202458 | — | — | 0.850 |
| 2 | TCGA-78-8655-01A-11R-2403-07 | — | cohortA1 | 0.836 |
| 3 | SRR1516086 | — | — | 0.797 |
| 4 | TCGA-E7-A8O7-01A-11R-A36F-07 | — | — | 0.794 |
| 5 | SRR8942997 | — | — | 0.789 |
| 6 | SRR8943026 | — | — | 0.787 |
| 7 | SRR12202456 | — | — | 0.778 |
| 8 | TCGA-05-4249-01A-01R-1107-07 | — | cohortA1 | 0.775 |
| 9 | MNG980 | — | — | 0.771 |
| 10 | MNG776 | — | — | 0.763 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.440 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.330 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.320 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.290 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.230 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.220 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.170 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.140 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.130 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.130 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.120 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.110 | Temsirolimus | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |
| APOPTOSIS | 0.080 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.060 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.060 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.030 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.010 | Idelalisib | — uncovered |